G2GBio Inc.

G2GBio Inc. is a pharmaceutical company specializing in the research, development, and manufacture of advanced drug delivery systems, particularly long-acting injectable medications. Its core mission is to enhance patient convenience and medication adherence, with an emphasis on chronic diseases such as dementia, diabetes, post-operative pain, osteoarthritis, and schizophrenia. G2GBio stands out in the biotechnology sector for its proprietary InnoLAMP technology, which enables precise and scalable production of uniform biodegradable microspheres for sustained drug release. This platform supports diverse applications and allows drugs to be released over extended periods, ranging from one week to several months, thereby addressing significant unmet medical needs in chronic disease management. The company operates a GMP-compliant facility and has formed strategic partnerships with both domestic and international pharmaceutical firms to expand its pipeline and technology deployment. Founded in 2017, G2GBio has rapidly become a notable player in biopharmaceutical innovation, particularly by minimizing production barriers and facilitating global access to high-quality medication solutions for aging and underserved populations.